Hepatocellular Carcinoma Clinical Trial
Official title:
Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study
NCT number | NCT02174575 |
Other study ID # | TMDU-1490 |
Secondary ID | |
Status | Withdrawn |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | July 2014 |
Est. completion date | May 2023 |
Verified date | May 2023 |
Source | Tokyo Medical and Dental University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
- It has been shown that patients who undergo liver resection surgery are at high risk for postoperative acute kidney injury (AKI). - Sevoflurane may increase the risk for postoperative AKI because of production of compound-A. - Therefore, we have planned to investigate the effects of different anesthetic agents on postoperative renal function. - Patients undergoing liver resection surgery are randomized into 2 groups. - One of the groups receives sevoflurane and the other group receives desflurane. - Blood and urine specimen are sampled both pre- and postoperatively, and several biomarkers are compared between the groups.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | May 2023 |
Est. primary completion date | May 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Forty adult patients (20 patients in each group) who are planned to undergo liver resection surgery are included. Exclusion Criteria: - Patients who undergo less invasive resection surgery under thoracoscopy or laparoscopy are excluded. Patients with chronic kidney disease, or allergic to any anesthetic agents used in the study are also excluded. |
Country | Name | City | State |
---|---|---|---|
Japan | Tokyo Medical and Dental University | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Tokyo Medical and Dental University |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Postoperative acute kidney injury | Postoperative acute kidney injury is defined based on RIFLE creatinine criteria. | within 72 hours postoperatively | |
Secondary | Urine IL-6 concentration | Urine IL-6 concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Plasma NGAL concentration | Plasma NGAL concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Urine NGAL concentration | Urine NGAL concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Serum cystatin C concentration | Serum cystatin C concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Urine L-FABP concentration | Urine L-FABP concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Urine NAG concentration | Urine NAG concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 | |
Secondary | Urine albumin concentration | Urine albumin concentration is measured pre- and postoperatively to detect subclinical acute kidney injury. | On the day of surgery and postoperative day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |